Ofatumumab
Evidence-based neurology checklist on ofatumumab: Pharmacology Ofatumumab is an anti-CD20 monoclonal antibody It induces B cell lysis It has demonstrated better efficacy than Teriflunomide Dose Side effects Acronym
Pharmacology
- Ofatumumab is an anti-CD20 monoclonal antibody
- It induces B cell lysis
- It has demonstrated better efficacy than Teriflunomide
Dose
Side effects
Acronym
References
- Kish T. Promising multiple sclerosis agents in late-stage development. P T 2018; 43:750-772.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383:546-557.
- Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology 2018; 90:e1805-e1814.
- Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014; 82:573-581.
- Rotstein DL, Halani S, Vadas P, Marriott JJ. Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies. Mult Scler 2026 (Online ahead of print).
